Septerna, Inc. (NASDAQ:SEPN - Get Free Report) shares traded down 7.2% during trading on Friday . The company traded as low as $13.20 and last traded at $13.19. 71,535 shares were traded during trading, a decline of 67% from the average session volume of 216,240 shares. The stock had previously closed at $14.21.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an "overweight" rating and a $38.00 price target on the stock. Wells Fargo & Company started coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an "overweight" rating and a $43.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $50.00 price objective on shares of Septerna in a research report on Tuesday. Finally, TD Cowen started coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a "buy" rating on the stock.
Check Out Our Latest Report on SEPN
Septerna Trading Down 13.6 %
The company has a 50-day moving average price of $20.46.
Hedge Funds Weigh In On Septerna
Several large investors have recently added to or reduced their stakes in SEPN. New York State Common Retirement Fund bought a new position in Septerna in the 4th quarter valued at about $32,000. PNC Financial Services Group Inc. bought a new position in Septerna in the 4th quarter valued at about $61,000. SG Americas Securities LLC bought a new position in Septerna in the 4th quarter valued at about $185,000. Corebridge Financial Inc. bought a new position in Septerna in the 4th quarter valued at about $212,000. Finally, M&T Bank Corp bought a new position in Septerna in the 4th quarter valued at about $376,000.
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
See Also
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
